The company aims to release an initial tissue-based prognostic this year, with a less-invasive sponge-sampling version for screening high-risk individuals to follow in 2023.
The firm's platform, dubbed HNKlear, uses methylation-specific PCR to detect microRNA biomarkers in a patient's blood sample following frontline cancer treatment.
Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The JHU technology leverages an epigenetic biomarker panel and a sponge-on-a-string collection device, as well as a PCR-based method, to detect Barrett's esophagus.
The firm believes that data from a recently published study illustrates the advantages of its technology for methylation-specific PCR assays.